biosimilars
Clinical tips: Biologicals and biosimilars
Biosimilars and the pharmacist’s role in their supply remains controversial, writes Carlene McMaugh Biological pharmaceutical products have been a part of the landscape of therapeutics for a number of years …
Biosimilars—here to stay
This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free. Username or Email Address Password Remember Me Register …
New biosimilars listed on the PBS
Here’s what you need to know While there are not many biosimilars available yet in Australia, several have been added to the ARTG and PBS this year. Biosimilar medicines are …
A wake-up call
A recent survey found that pharmacist comfort with supplying biosimilars is going backward, so what can be done to turn this around? In 2018, 361 community pharmacists were surveyed across …
Biologics switching is in pharmacists’ scope
Pharmacists’ authority to use their expertise to substitute one medicine for another should also apply to biological medicines, says FIP The International Pharmaceutical Federation has published a revised Statement of …
New biosimilars course
Guild Learning and Development is partnering with MSD Australia in an online course titled Biosimilars in focus This is the first of two courses to be launched on this topic …
Innovative medicines prices to drop
Medicines Australia and the Government have signed a five-year agreement which will see innovative medicines reduced in price over 15 years The organisation says the Strategic Agreement will support ongoing …
Caution required for biosimilars
While they present a cost-saving opportunity, safety data on biosimilars is still limited, warns IBD specialist There is an absence of data on adverse reactions or potential development of anti-drug …
Biosimilars: what’s in a name?
The way a biosimilar is named may affect whether a pharmacist is willing to substitute it for a brand name biologic, a new study has found. The study, published in …
GBMA welcomes PBS listing of infliximab
The inclusion of the first monoclonal antibody biosimilar on the PBS will deliver immediate savings to the Federal Government; however the full potential of this and other biosimilar medicines relies …
Inflectra to be PBS listed from December
Pfizer today confirmed that the first mAb biosimilar, Inflectra (infliximab), will be added to the PBS on 1 December 2015 for the treatment of eight inflammatory conditions.
Generic Medicines Working Group identifies priorities
Four policy priorities that will safeguard affordable access to medicines in Australia while ensuring the generic and biosimilar medicines industry remains viable have been agreed to by the Federal Government. …